Founded in 2013, Eleusis is a clinical-stage life science company dedicated to unlocking the full therapeutic potential of psychedelics, guided by science and enabled by drug discovery, clinical development and care delivery design. The company’s comprehensive discovery and development capabilities, together with Andala’s care delivery platform, enable it to target a broad spectrum of unmet needs within psychiatry and beyond psychiatry.
Location: United Kingdom, England, Westminster
Member count: 11-50
Founded date: 2013
Investors 3
Mentions in press and media 4
| Date | Title | Description | Category | Author | Source |
| 20.01.2022 | Psychede... | Psychedelics biotech Eleusi... | Financing | Paul Schlo... | endpts.com... |
| 03.06.2021 | Psychedeli... | The UK’s first investment fund... | - | Dan Taylor | tech.eu/br... |
| 07.01.2020 | Transformi... | Research on psychedelics, whic... | - | - | statnews.c... |
| - | Psychedeli... | The UK’s first investment fund... | - | Dan Taylor | tech.eu/20... |